JPM25: Kyverna CEO sets priorities for CAR-T autoimmune biotech
Jan 13, 2025 · About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the California biotech, which aims to deliver the first …
KYV-5 - jproc.ca
The KYV-5 is a small unit that attaches to the front of the larger CV-3591 converter. That's real easy to see in the 3/4 photo below. The TACTERM normal configuration consists of the Basic …
CAR T-Cell Therapy for Autoimmune Diseases | Kyverna
Learn how we're developing advanced CAR T-cell therapies for autoimmune diseases. This therapeutic approach may help reset the patient’s immune system and offer sustained …
KYV-5 TACTERM - Crypto Museum
TSEC/KYV-5 (TACTERM) is an Advanced Narrowband Digital Voice Terminal (ANDVT), introduced in 1980 by the US National Security Agency (NSA) and manufactured by ITT …
Product Pipeline of B-Cell Targeting Therapies | Kyverna
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B …
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities …
Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase 2 trials for stiff person syndrome and myasthenia gravis, and two …
Kyverna Therapeutics Advances CAR T Pipeline With 40% Phase 2 ...
Jan 13, 2025 · Kyverna Therapeutics (NASDAQ: KYTX) announced its 2025 strategic priorities, focusing on developing CAR T cell therapies for autoimmune diseases. The company reported …
FDA Clears Phase 2 KYSA-7 Study of CAR T-Cell Therapy in …
Jan 5, 2024 · According to an announcement, the FDA has cleared Kyverna Therapeutics’ investigational new drug application (IND) to test KYV-101, a CAR T-cell therapy, in patients …
Kyverna Therapeutics to Present Data on 50 Patient Experience at ...
Jun 7, 2024 · With 50 patients treated so far with the CAR in KYV-101 in both oncological and autoimmune conditions at more than 15 locations in Europe and the U.S., we believe that the …
Kyverna wins RMAT designation for stiff-person syndrome for cell ...
Jul 16, 2024 · Six months after winning fast track status for multiple sclerosis, Kyverna Therapeutics’ KYV-101 has secured another US Food and Drug Administration (FDA) …